MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$7,072,124
EPS
-$0.57
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
General and administrative
1,717,231
1,680,375
1,219,846*
1,912,829
Research and development
1,790,859
1,724,872
3,256,098*
2,436,971
Total operating expenses
3,508,090
3,405,247
4,475,944
4,349,800
Loss from operations
-3,508,090
-3,405,247
-4,475,944*
-4,349,800
Interest income
30,079
42,160
114,432*
100,921
Other income, net
14,926
33,916
4,731*
71,456
Loss on issuance of warrants
726,427
-
-
-
Warrant issuance costs
755,233
-
-
-
Change in fair value of warrant liability
2,127,379
-
-
-
Net loss
-7,072,124
-3,329,171
-4,356,781
-4,177,423
Basic EPS
-0.57
-0.3
-0.393
-0.39
Diluted EPS
-0.57
-0.3
-0.393
-0.39
Basic Average Shares
12,423,174
11,253,030
11,076,407
10,833,393
Diluted Average Shares
12,423,174
11,253,030
11,076,407
10,833,393
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$7,072,124
(-63.29%↓ Y/Y)
Interest income
$30,079
(-73.79%↓ Y/Y)
Other income, net
$14,926
(-92.76%↓ Y/Y)
Loss from operations
-$3,508,090
(24.59%↑ Y/Y)
Change in fair value of
warrant liability
$2,127,379
Warrant issuance costs
$755,233
Loss on issuance of
warrants
$726,427
Total operating
expenses
$3,508,090
(-24.59%↓ Y/Y)
Research and development
$1,790,859
(-41.64%↓ Y/Y)
General and
administrative
$1,717,231
(8.44%↑ Y/Y)
Buy us a coffee
Lantern Pharma Inc. (LTRN)
Lantern Pharma Inc. (LTRN)